Holen Sie sich die Stockscreener-App
0.686
7.36%
0.047
Handel nachbörslich:
.68
-0.006
-0.87%
Schlusskurs vom Vortag:
$0.639
Offen:
$0.65
24-Stunden-Volumen:
970.15K
Relative Volume:
1.77
Marktkapitalisierung:
$56.74M
Einnahmen:
$38.70M
Nettoeinkommen (Verlust:
$-117.88M
KGV:
-0.4035
EPS:
-1.7
Netto-Cashflow:
$-92.84M
1W Leistung:
-2.13%
1M Leistung:
-8.47%
6M Leistung:
-23.74%
1J Leistung:
-47.23%
1-Tages-Spanne:
$0.64
$0.693
1-Wochen-Bereich:
$0.5842
$0.7137
52-Wochen-Spanne:
$0.4471
$1.6399
Adicet Bio Inc Stock (ACET) Company Profile
Firmenname
Adicet Bio Inc
Sektor
Branche
Telefon
617-482-2333
Adresse
131 DARTMOUTH STREET, BOSTON
Vergleichen Sie ACET mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
0.686 | 49.33M | 38.70M | -117.88M | -92.84M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-30 | Fortgesetzt | Guggenheim | Buy |
| 2024-09-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-06-27 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-06-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-03-31 | Eingeleitet | SMBC Nikko | Outperform |
| 2022-03-08 | Eingeleitet | Truist | Buy |
| 2022-03-04 | Eingeleitet | Jefferies | Buy |
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2021-04-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-04-08 | Eingeleitet | Guggenheim | Buy |
| 2020-11-04 | Eingeleitet | B. Riley Securities | Buy |
| 2020-10-27 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-16 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Adicet Bio Inc Aktie (ACET) Neueste Nachrichten
Citizens JMP maintains Market Perform rating on Adicet Bio stock By Investing.com - Investing.com UK
Adicet Bio (ACET) Upgraded to Buy: Here's Why - Yahoo Finance
What makes Adicet Bio Inc. stock price move sharplyFree Top 5 Picks of the Week - thegnnews.com
What is the next catalyst for Adicet Bio Inc.Squeeze Play Stock Candidates - mustnews.co.kr
MaxCyte Signs Strategic Platform License with Adicet Bio for Cancer and Autoimmune Diseases Treatments. - AInvest
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio - Yahoo Finance
Adicet Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
MaxCyte signs platform license agreement with Adicet Bio for Gamma Delta T cell therapies - SelectScience
Layoff Tracker: Bicycle, Tune, Iovance, Precision Downsize to Conserve Cash - BioSpace
MaxCyte signs platform license agreement with Adicet Bio - MSN
JonesTrading Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $4 - 富途牛牛
Adicet Bio Reports Q2 2025 Financial Results - The Globe and Mail
Adicet Bio: Strategic Advancements and Financial Prudence Drive Analyst's Buy Rating - AInvest
Adicet Bio: Strategic Advancements and Financial Prudence Drive Buy Rating - TipRanks
Adicet Bio Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Adicet Bio (ACET) Q2 Loss Widens 3% - AOL.com
Adicet Bio reports Q2 EPS (34c), consensus (30c) - TipRanks
Adicet Bio Clinical Trial Now Targets 6 Autoimmune Diseases as Company Streamlines for Growth - Stock Titan
Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference - BioSpace
MaxCyte Partners with Adicet Bio for Gamma Delta T Cell Therapy Platform License Agreement - AInvest
MaxCyte Inks Strategic Platform License with Adicet Bio, Entitled to Licensing Fees and Revenue - AInvest
Maxcyte signs platform license agreement with Adicet Bio - MarketScreener
MaxCyte Signs Platform License Agreement with Adicet Bio - The Manila Times
MaxCyte, Adicet Bio Sign Strategic Platform License Agreement - AInvest
MaxCyte Expands Cell Therapy Reach: Strategic License Deal Powers Adicet's Cancer Treatment Innovation - Stock Titan
What are Adicet Bio Inc. company’s key revenue driversAchieve rapid portfolio growth with smart picks - Jammu Links News
Is it the right time to buy Adicet Bio Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What markets is Adicet Bio Inc. expanding into Is AMZE stock a good long term investment optionTriple-digit return opportunities - Jammu Links News
What drives Adicet Bio Inc. stock priceBuild a diversified portfolio for steady growth - Jammu Links News
Why is Adicet Bio Inc. stock attracting strong analyst attentionMaximize returns with disciplined trading approaches - Jammu Links News
Should I hold or sell Adicet Bio Inc. stock in 2025Unmatched profit potential - Jammu Links News
What is the risk reward ratio of investing in Adicet Bio Inc. stockFree Consultation - Jammu Links News
How does Adicet Bio Inc. compare to its industry peersFastest-growing stock picks - Jammu Links News
What institutional investors are buying Adicet Bio Inc. stockNavigate the market with precision tools - Jammu Links News
Is Adicet Bio Inc. stock overvalued or undervaluedBuild wealth with steady, reliable stocks - Jammu Links News
When is Adicet Bio Inc. stock expected to show significant growthFastest return on investment - Jammu Links News
How does Adicet Bio Inc. generate profit in a changing economyMarket-crushing profits - Jammu Links News
What are the technical indicators suggesting about Adicet Bio Inc.Track top-performing stocks effortlessly - Jammu Links News
Building trade automation scripts for Adicet Bio Inc.Low Exposure Strategy with Sector Analysis - Newser
How high can Adicet Bio Inc. stock price go in 2025Free Daily Momentum Screener With Alerts - Newser
Tools to monitor Adicet Bio Inc. recovery probabilityPattern Recognition Tool for ROI Investors - Newser
Sentiment analysis tools applied to Adicet Bio Inc.AI Enhanced Strategy for Portfolio Growth - Newser
Pattern recognition hints at Adicet Bio Inc. upsideBreakout Screener With Alert Based Timing - Newser
Custom watchlist performance reports with Adicet Bio Inc.Predictable Return Plan with Entry Guidance - Newser
Advanced analytics toolkit walkthrough for Adicet Bio Inc.Market Sentiment Tracker with Smart Alerts - Newser
How Adicet Bio Inc. stock performs during market volatilityInvestment Roadmap for High Potential Stocks - Newser
Adicet Bio Inc. stock trend outlook and recovery pathTrading Volume Spike and Reversal Analysis - Newser
Finanzdaten der Adicet Bio Inc-Aktie (ACET)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):